Akero ’s NASH candidate reduces liver fat in patients taking a GLP-1
Akero Therapeutics said its NASH drug reduced liver fat in patients who were also taking a GLP-1 agonist. The NASH-focused biotech on Monday released topline data from a Phase IIb trial for 32 patients with type 2 diabetes and F1-F3 liver fibrosis due to NASH who…#glp1 #nash #2diabetes #f1f3 #symmetry #f1 #f3 #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news